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ABSTRACT
Dysphagia can be caused by mechanic or neurologic disorders. Neurologic 
dysphagia is commonly related to cerebrovascular disease, parkinson disease, 
amyotropic lateral sclerosis, tardive dyskinesia, and myasthenia gravis (MG). 
About 15-40% dysphagia occurred in MG generalized type. Only 6% MG with 
dysphagia were reported as a single symptom. The case reports aimed to 
demonstrate the role of otolaryngologist in multidisciplinary approach of the 
MG management. Two cases of MG were reported. First case was a 33 years 
old woman with moderate MG generalized type with ocular, dysphagia, and 
disarthria symptoms and second case was a 46 years old man with acute 
severe MG with crisis. Management therapy was applied according to onset 
and severity of MG. Acetylcholinesterase (AChE) and corticosteroid were 
administered for the first case, whereas therapeutic plasma exchange (TPE) 
for second case. In conclusion, disfagia in MG can be accompanied with other 
symptom, therefore its management should be based on the severity in order 
to give a positive result.
ABSTRAK
Disfagia dapat disebabkan oleh gangguan mekanik maupun motorik. Disfagia 
akibata gangguan saraf umumnya dikaitkan dengan penyakit cerebrovaskuler, 
parkinson, amyotropic lateral sclerosis, tardive dyskinesia dan miastenia 
gravis (MG). Sekitar 15-40% disfagia terjadi pada MG tipe generalisata. Hanya 
6% disfagia dilaporkan sebagai gejala tunggal pada MG. Laporan kasus ini 
bertujuan memberikan gambaran peran ahli THT dalam  penatalaksanaan MG 
secara multidisiplin. Dua  kasus disfagia akibat  MG telah dilaporkan. Kasus 
pertama adalah wanita berumur 33 tahun dengan MG tipe generalisata derajat 
sedang dengan gejala ocular, disfagia dan disartria. Kasus kedua seorang seorang 
pria berumur 46 tahun dengan MG akut berat dengan krisis. Penatalaksanaan 
terapi dilakukan menurut onset dan keparahan MG. Asetilkolinesterase 
(AChE) dan kortikosteroid diberikan untuk kasus pertama, sedangkan terapi 
pertukaran plasma (TPP) untuk kasus kedua. Dapat disimpulkan, disfagia pada 
MG dapat desertai gejala lain sehingga tatalaksananya harus diberikan sesuai 
derajat keparahan penyakit agar memberikan respon yang baik.   
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INTRODUCTION
Dysphagia is a symptom of various 
diseases due to congenital and/or certain 
systemic disorders. The prevalence of 
dysphagia ranges from 7-22% in people 
over 50 years. Risk factors for dysphagia 
are old age, gastric acid reflux, stroke, 
head and neck malignancy, head trauma, 
Parkinson’s disease, multiple sclerosis, 
muscular dystrophy, and myasthenia 
gravis (MG).1,2 Myasthenia gravis is a rare 
autoimmune disease that causes muscle 
weakness. The disorder underlying this 
disease is the presence of antibodies 
that attack the nicotinic receptors in the 
neuromuscular junction. The prevalence 
of MG is about 20 cases per 100,000 lives. 
The highest incidence occurs in women 
over 40 years and even higher in men 
over 50 years.1 Myasthenia gravis is 
classified into two types, namely ocular 
MG (10%) and generalized MG (90%). 
This disease can worsen in a matter of 
weeks or months.3,4
Dysphagia in MG cases is around 
15 - 40% of patients with generalized 
MG. It can be a single symptom or 
as a accompanying symptom. Only 
6% cases manifested dysphagia as 
a single symptom of MG.2 Patients 
with dysphagia due to MG need 
appropriate management involving 
multidisciplinary approach in order to 
obtain a optimal result.2,5,6 Assessment 
of dysphagia includes the existence of 
impaired swallowing function, the level 
of anatomy involved, and the underlying 
disease. Management of MG has several 
therapeutic modalities that can be given 
based on the severity and onset of MG.7 
The purpose of this paper was to report 
two cases of dysphagia in MG and their 




A 33-year-old woman came with 
a chief complaint of hard to swallow. 
The patient had been complaining of 
difficulty in swallowing for two months 
that felt increasingly worsen. The 
patient must exert energy to swallow. 
The patient could only eat a little 
ammount of porridge with the help 
of gulping water. The patient did not 
choke or cough when eating or drinking. 
The patient experienced nasal voice 
after talking for a long time. Shortness 
of breath sometimes felt. The patient 
was often sleepy and the eyelids closed 
themselves during the daytime. There 
was no blurred or double vision. No 
complaints of limb weaknesses. The 
patient had been experiencing nasal 
voice after talking for a long time for 
five months and the patient often felt 
sleepy during the day. The patient did 
not complain of difficulty in swallowing, 
limb weakness, or shortness of breath. 
The patient was already treated at the 
Neurology Department of the regional 
hospital to get 2 kinds of drugs and the 
complaints were improved. A history 
of such illness was denied. History 
of high blood pressure and history of 
diabetes mellitus (DM) were denied. No 
family member who had such disease 
previously. The patient was a housewife, 
with low socioeconomic status.
The physical examination found 
good general condition, good level of 
awareness. Vital signs were within 
normal limits. Mesocephalic head, 
symmetrical face, eyes were within 
normal limits. Neck lymph node 
enlargement was absent. Heart, lung, 
and abdomen examination results 
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were within normal limits. There were 
no limb weaknesses. At the time of the 
drinking test, the patient could drink 100 
cc of water, more than 10 sec, and did 
not choke or cough while drinking and 
did not vomit.
Local status of ear, nose, and throat 
were within normal limits. Positive 
gag reflex. Laboratory blood tests were 
within normal limits. Chest x-ray in 
anteroposterior and lateral position 
showed no abnormalities. The results 
of oesophagographic examination 
showed a partial narrowing of 1/3 
proximal of the oesophagus, which 
concluded of suspected esophagitis. 
The main diagnosis was pharyngeal 
phase of dysphagia with the suspected 
neuromuscular abnormalities.
FIGURE 1. Esophagography
Consultation results from the 
Department of Neurology found good 
general condition, GCS of 15. Eyes: 
isochoric pupils, pupillary reflexes +/+, 
neck: stiff neck (-). Cranial nerve: within 
normal limits, sensibility, vegetative, 
and motoric functions were within 
normal limits. Watenberg test (+), count 
test: hypotonia (+). EMG examination 
showed a decrease of >20% on repetitive 
stimulation of 20 Hzin left flexor carpi 
ulnaris muscle which could support 
the diagnosis of MG. The Neurology 
Department assessments were 
dysarthria and dysphagia due to MG. The 
patient gave her informed consent prior 
and then underwent FEES examination. 
The results of FEES examination 
showed pharyngeal phase of dysphagia 
due to neuromuscular disorder (MG), 
no aspiration signs were obtained. 
Patients were advised for soft diets and 
swallowing muscle physiotherapy. The 
results of MSCT Scan of thorax showed 
no abnormalities, no visible lung mass or 
mediastinal mass, no thymoma.
The patient was given RL infusion 
therapy of 20 drip per minute, injection 
of methyl prednisolone 125 mg/12 h IV 
for 4 days then tappering off, mestinon 60 
mg/6 h orally. On day 4 of the treatment, 
the patient did not complain of difficulty 
in swallowing and there were no 
complaints of nasal voice. The patient 
was tested, and could drink 100cc in less 
than 4 sec. The patient was discharged on 
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the 7th day of treatment (after tappering 
off) and recommended to do a follow-
up examination in one week with home 
therapy of 60 mg of mestinon/6 h orally.
One week later the control, the 
patient went to the ENT clinic and 
there were no complaints of difficulty 
in swallowing or nasal voice. Patients 
were given 60 mg/8 h of pyridostigmine 
therapy orally.
Case II
A 46-year-old male consulted from 
the Department of Neurology with 
major complaints of difficult to swallow. 
The patient had been complaining of 
difficulty in swallowing for a week, 
even hard to swallow saliva, had nasal 
voice, and eyes closed themselves. The 
complaints increasingly aggravated 
and did not improve after patients 
took mestinon. The patient sometimes 
experienced shortness of breath and 
cough. The patient had been complaining 
of difficulty in swallowing for six months, 
swallowing food should be encouraged 
with drinking water, had nasal voice, 
and both eyes often closed themselves. 
Complaints felt worsen in the afternoon 
and evening. Patient went to the regional 
hospital and was given mestinon drugs 
taken 2 times a day. After taking the 
medicine, the complaint felt better.
A previous history of such illness was 
denied. History of high blood pressure 
and DM was denied. No family member 
who had such illness previously. The 
patient was an employee, treated using 
health insurance, socio-economic status 
was sufficient.
On physical examination found 
good general condition, good level of 
awareness. The patient had been installed 
NGT, vital signs were within normal 
limits. Mesocephalic head, symmetrical 
face, isochoric pupils, ptosis of right 
eye. Throat examination showedno 
gag reflex, nose and ears examination 
results were within normal limits. Heart, 
lungs, and abdomen examinations 
results were within normal limits. There 
were no limb weaknesses. Physiological 
reflexes of the upper and lower limbs 
were normal. Pathological reflexes were 
not found. There were 9th and 10th nerve 
palsy. Watenberg test was positive.
Chest X-ray did not reveal any 
infiltrates on the lungs. MSCT scan of the 
head without contrast showed lacunar 
infarction in posterior crus of the left 
and right internal capsule. Results of 
blood laboratory examination showed 
hypernatremia (152 mmol/L), and other 
parameters were within normal limits. 
EMG showed a decrease in repetitive 
nerve studies in 3Hz, 8Hz, and 20 Hz 
stimuli that support the diagnosis of MG. 
Therapy was continued.
Clinical diagnosis: 9th and 10th 
cranial nerve palsy, dysarthria, 
dysphagia. Topical diagnosis: suspected 
neuromuscular junction, and etiological 
diagnosis: 1. MG. 2. Non-hemorrhagic 
stroke. Joint care with the department of 
Medical Rehabilitation, Clinical Nutrition, 
and ENT. Patients received O2 of 3 L/min 
through nasal cannula, RL infusion of 
20 drip per min, mestinon 1 tablet/6 h, 
prostigmin injection of 1 ampul/8 h IV, 
injection of methylprednisolone 125 
mg/12 h IV, vitamin B1, B6, B12 1 tablet/8 
h orally.
The assessment of the otolaryngology 
department was pharyngeal phase of 
dysphagia with the 9th and 10th cranial 
nerve palsy. Fiberoptic endoscopy 
evaluation of swallowing was conducted 
with the result of pharyngeal phase 
of dysphagia from neuromuscular 
abnormalities, silent aspiration was 
obtained. NGT is maintained. One week 
of the treatment, the patient could not 
swallow saliva resulting in salivary 
retention and shortness of breath. The 
patient was transferred to the ICU due to 
the threat of respiratory failure and MG 
crisis. The chest X-ray showed duplex 
pleural effusion and perihilar infiltrate. 
The therapy was continued with O2 of 10 
L/min through mask and nebulisation 
was done. Patients were programmed 
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for therapeutic plasma exchange (TPE) 6 
times every 2-3 days. After the first TPE, 
the patient underwent improvement, 
complaints of shortness of breath were 
reduced, nasal noise was reduced, 
difficulty in swallowing was reduced 
and ptosis was improved. After the 5th 
TPE, methylprednisolone injection was 
tapered off for 3 days and the patient 
was given mestinon 60 mg/6 h orally. 
The patient’s clinical condition was 
improved after the 6th TPE and the NGT 
was removed.
FEES examination for evaluation 
of therapy was conducted after TPE 
was completed. The test results showed 
no sign of dysphagia. The patient was 
discharged with mestinon therapy 60 
mg/ 6 h orally. He had given his written 
informed consent before.
DISCUSSION
Patients with dysphagia need a 
comprehensive examination from the 
history of illness, physical examination 
including neurological examination, 
and laboratory examination. Laboratory 
examinations include the detection of 
acetylcholine receptors (AChR) which can 
help to look for the causes of dysphagia 
due to MG, measurement of muscle 
enzymes for inflammatory myopathy, 
or thyroid function tests to enforce 
toxic myopathy.3 Another supportive 
examinations for dysphagia are barium 
esophagography, videofluoroscopic 
swallowing study (VFSS), fiberoptic 
endoscopic evaluation of swallowing 
(FEES) test, upper endoscopy, and 
esophageal manometry.3
Myasthenia gravis is a rare 
autoimmune disease that causes muscle 
weakness. The disorder underlying this 
disease is the presence of antibodies 
that attack the nicotinic receptors in 
the neuromuscular junction.2,5 The 
prevalence of MG is about 20 cases per 
100,000 lives. The highest incidence 
occurs in women over 40 years and even 
higher in men over 50 years.2
The typical clinical feature of MG is 
fluctuating muscle weakness, especially 
after activity. The weaknesses include 
weakness of the eye and facial muscles, 
namely ptosis, diplopia and facial muscle 
weakness. Bulbar muscle weaknesses 
are nasal sounds, nasal regurgitation, 
difficulty in chewing, difficulty in opening 
the jaw, difficulty in swallowing or 
coughing when eating or drinking which 
can cause aspiration complications. 
Muscle weakness occurred in the upper 
limb is more frequent than in the lower 
limb. Respiratory muscle weakness, 
intercostal and diaphragmatic muscles 
weakness, causes CO2 retention and 
hypoventilation, which can cause 
neuromuscular emergencies.6 Both of 
the cases above showed pharyngeal 
phase of dysphagia which was caused by 
neuromuscular disorder.
Clinical classification of MG according 
to Osserman can be divided into five 
groups i.e. 1) Ocular MG, which only 
attacks the ocular muscles, accompanied 
by ptosis and diplopia. Very mild, no 
cases of death; 2) Mild generalized MG, 
slow onset, usually in the eyes, gradually 
spread to the skeletal and bulbar 
muscles. The respiratory system is not 
affected. The response to pharmacology 
therapy is good. Low mortality rate; 
3) Moderate generalized MG, gradual 
onset and is often accompanied by 
ocular symptoms, then continues to get 
more severe with the attack of all the 
skeletal and bulbar muscles. Dysarthria, 
dysphagia, and difficulty of chewing are 
more evident than in mild myasthenia 
gravis. The respiratory muscles are not 
affected. The response to pharmacology 
therapy is less satisfactory and patient’s 
activity is limited, but the mortality rate 
is low;  4) Acute severe MG, rapid onset 
with the severe weakness of the skeletal 
and bulbar muscles accompanied by the 
start of breathing muscles weakness. 
The disease usually develops maximally 
within six months. Poor response to 
pharmacology therapy. The incidence 
of miastenic, cholinergic, and combined 
287
J Med Sci, Volume 52, Number 3, 2020, July: 282-291
crisis are high. High mortality rate;  5) 
Advanced severe MG, arises at least 2 
years after the onset of symptoms of 
group I or II. MG develops slowly or 
suddenly. The response to drugs and the 
prognosis is poor.6, 7
Case I was classified as moderate 
generalized MG, in which patients had 
ocular symptoms with dysarthria and 
dysphagia. The patient have a good 
treatment response. Case II was classified 
as acute severe MG where the patient had 
a MG crisis and had a poor response to 
the administration of anticholinesterase 
inhibitors and improved after TPE was 
done.
The cause of MG is the presence of 
antibodies to the nicotinic type of AChR 
receptor (anti-ACHR). The amount of 
AChR in the postsynaptic membrane 
is reduced due to the presence of anti-
AChR. Anti-AChR is found in 80-90% of 
the MG patients. The cause of antibody 
production is based on the majority 
theory which states that about 80% of 
patients with MG have abnormalities in 
the thymus or thymoma.6
A simple examination, Ptosis, can 
be performed to establish a diagnosis of 
MG. Ptosis can be assessed by closing the 
eyelid in 30 sec or less when the patient 
is told to look up at one point (Watenberg 
test). Bulbar muscle weakness can be 
assessed by having the patient count 
to 50, then there will be nasal or weak 
voice. Respiratory muscle weakness can 
be assessed by asking the patient to take 
a deep breath and exhale strong breath 
through the nose, a weak breath and 
cough accompanied by tachypnea or 
tachycardia can support the diagnosis of 
MG.7
Investigations to establish MG 
diagnosis include 1) Assessment of 
acetylcholine anti-receptor antibodies. 
These antibodies are specific for MG 
and are very useful for establishing 
the diagnosis. These antibody titers are 
elevated in 90% of patients with MG in 
groups IIA and IIB, and 70% in group I. 
These antibody titers generally correlate 
with the severity of the disease. 2) Skeletal 
anti-muscle antibodies, these antibodies 
are found in more than 90% of patients 
with thymoma and approximately 30% 
of patients with MG. Patients who have 
no antibodies in their serum and also no 
anti-acetylcholine receptor antibodies, 
then the possibility of thymoma is 
very small. 3) Tensilon (edrophonium 
chloride) test, tensilon is a cholinesterase 
inhibitor. This test is very useful if the 
examination of anti-acetylcholine anti-
receptor antibodies cannot be done, 
or the test results are negative while 
clinically still suspected of MG. If there 
are no side effects after giving 1-2 mg 
tensilon intravenously, then 5-8 mg of 
tensilon is injected again. The reaction 
is considered positive if there is a clear 
improvement in muscle strength (for 
example within 1 min), disappearance of 
ptosis, the arm can be held in a longer 
abduction position, and increased vital 
capacity. 4) Prostigmin test, prostigmin of 
0.5-1.0 mg mixed with 0.1 mg of atropine 
sulphateare injected intramuscularly or 
subcutaneously. The test is considered 
positive if symptoms disappear and 
energy improves. 5) Repetitive nerve 
stimulation test, a decrease in the 
amplitude of the combined muscle action 
potential with repeated stimulation of 
the peripheral nerve with a frequency 
of 3 Hertz (decremental response). 6) 
Single fiber EMG test, the method is 
more sensitive, there is an increase in 
the interpotential interval.6,8
Both of the reported cases obtained 
positive Wartenberg test, positive speech 
test, decreamenton repetitive stimulation 
test that supported the diagnosis of 
MG. MG management has 4 choices, 
namely: improving neuromuscular 
transmission with AChE inhibitor such 
as pyridostigmine (mestinon), treatment 
of acute exacerbations with TPE, 
immunoadsorption, and intravenous 
immunoglobulin, immunosuppression, 
and thymectomy. Myasthenia gravis 
therapy options can be given according 
to the onset of the disease.6
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FIGURE 2. The choice of MG therapy according to the onset of the disease.6
Acetylcholinesterase inhibitors, 
work by inhibiting the formation of the 
cholinesterase enzyme which functions 
to break down acetylcholine, thereby 
indirectly increasing acetylcholine 
levels. Giving AChE can improve muscle 
weakness that occurs within hours 
but does not affect the course of the 
disease. High doses of AChE can cause 
“cholinergic crisis” with symptoms of 
miosis, bradycardia, hypersalivation, 
bronchoconstriction, lacrimation and 
sweating.6
Immunosuppressants can be 
used in MG therapy. Azathioprine 
is still the first choice for long-
term immunosuppressants. 
Immunosuppression therapy such as 
azathioprine can be used on MG with a 
onset of several months. Corticosteroids 
are cheaper immunosuppressants. At 
the beginning of corticosteroids therapy, 
there is a risk of worsening of the disease. 
Long-term corticosteroid therapy must 
be avoided. Other immunosuppressant 
agents are cyclophosphamide and 
methotrexate.6
Plasmapheresis and intravenous 
immunoglobulin can be used in 
myasthenic crisis. The plasmapheresis 
technique separates plasma from 
cells using membrane filtration or 
centrifugation. The cell is re-infused 
immediately after the cell plasma is 
removed. Albumin, colloids, crystalloids 
are used to maintain fluid volume and 
balance. Plasma exchange has high 
limitations and morbidity, so special 
equipment and trained personnel are 
needed. High doses of immunoglobulin 
are given intravenously and can be given 
on severe MG.6
Non-pharmacological therapy can 
be given to MG patients. This therapy 
can be in the form of exercise therapy, 
namely extensive joint motion exercises, 
breathing exercises in the form of 
inspiration breathing muscle exercises 
to strengthen the breathing muscles, 
pursed lip breathing and abdominal 
breathing, resistance and strength 
training which were proven effective for 
muscle diseases, occupational therapy to 
train how the movements are performed 
effectively, speech therapy in patients 
who experience facial and throat muscle 
weakness, and counseling therapy.7
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FIGURE 3. Algorithm of MG management (Euro Myasthenia Guidelines)
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Patient I was given AChE and 
corticosteroid therapy. Administration 
of therapy was according to the patient’s 
MG degree and onset of the disease 
in order to eliminate MG complaints 
quickly. Patient II had an acute severe 
MG, the patient did not respond to 
AChE and corticosteroid administration. 
The patient experienced improvement 
by administering TPE which was 
the treatment of choice for acute 
exacerbation of MG. Both patients were 
consulted to the Medical Rehabilitation 
department to get physiotherapy to 
support the success of MG therapy.
CONCLUSION
It is concluded that in 2 cases of 
dysphagia with MG, it is necessary to 
determine the degree of the disease 
that would determine the management. 
The first case receives oral AChE and 
corticosteroids therapy and give a 
good response. The second case is 
given oral and intravenous AChE and 
corticosteroids therapy, and does not 
experience improvement. Giving 
plasmapheresis give a good response. 
Multidisciplinary collaboration of 
otolaryngologist, neurologist and other 
disciplines are needed to obtain an 
optimal results.
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